Vtesse, Inc., a company committed to developing drugs that will benefit patients with extremely rare, life-threatening diseases, secured $17 million in Series A funding in support of its global, pivotal clinical trial of VTS-270 for Niemann-Pick Type C1 disease (NPC).
The company's ongoing Phase 2b/3 prospective, randomized, double-blind, sham-controlled trial of VTS-270 is being conducted in patients affected by NPC disease. It is a three-part efficacy and safety trial of VTS-270, administered by the intrathecal route (IT) every two weeks, with planned enrollment of approximately 51 patients.
Partner Gary Schall counseled Vtesse.
For more information read Vtesse's press release.